Glucose-lowering therapies in type 2 diabetes—especially weight-reducing GLP-1 receptor agonists and SGLT2 inhibitors—should be judged by strength and physical performance, not lean-mass estimates alone, within a pragmatic cardiorenal-muscle framework for sarcopenia-prone patients.
Caloric restriction and dietary restriction may delay brain aging and lower risk of neurodegenerative and cerebrovascular disease via epigenetic, proteostasis/autophagy, anti-inflammaging, mitochondrial, and nutrient-sensing pathways, though clinical translation remains uncertain.
This evidence-based review concludes that many popular diet claims—including intermittent-fasting superiority over continuous restriction, DNA-based diets, superfoods, and carbs being uniquely fattening—are overstated, while energy balance, adequate protein (including on vegan diets), and no single ideal longevity diet are better supported.
Diet-shaped gut microbiota and their metabolites, especially short-chain fatty acids, form a gut–muscle axis that influences muscle metabolism, strength, function, and sarcopenia risk with aging.
A correction has been issued to a paper claiming that AMPK-upregulated microRNA-708 suppresses cellular senescence and aging by downregulating Disabled-2 and mTORC1 activation.